Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Eli Lilly and Co's share price for the quarter that ended in Mar. 2026 was $919.77. Eli Lilly and Co's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 894 Mil. Therefore, Eli Lilly and Co's market cap for the quarter that ended in Mar. 2026 was $821,814 Mil.
Eli Lilly and Co's quarterly market cap
increased
from Sep. 2025 ($683,527 Mil) to Dec. 2025 ($961,624 Mil) but then
declined
from Dec. 2025 ($961,624 Mil) to Mar. 2026 ($821,814 Mil).
Eli Lilly and Co's annual market cap
increased
from Dec. 2023 ($524,266 Mil) to Dec. 2024 ($692,899 Mil) and
increased
from Dec. 2024 ($692,899 Mil) to Dec. 2025 ($961,624 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Eli Lilly and Co's Enterprise Value for Today is $1,115,419 Mil.
Eli Lilly and Co (NYSE:LLY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Eli Lilly and Co Market Cap Related Terms
Eli Lilly and Co Market Cap Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Eli Lilly and Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (LLY) has a Market Cap of $1,077,331 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Eli Lilly and Co and its competitors. According to the industry distribution chart, Eli Lilly and Co ranks #1 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Eli Lilly and Co's Market Cap too high?
Eli Lilly and Co's current Market Cap is $1,077,331 Mil. The Drug Manufacturers industry median Market Cap is 205.37. Eli Lilly and Co's value of $1,077,331 Mil is 524480.5% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #1 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Market Cap compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #1 out of 1023 companies for Market Cap. This places Eli Lilly and Co in the top 0% of its industry — outperforming the majority of peers. The industry median Market Cap is 205.37. Eli Lilly and Co's value of $1,077,331 Mil is 524480.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Market Cap of $1,077,331 Mil is 524480.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Market Cap is $1,077,331 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is $1,409.61, compared to a current price of $1,208.12 — trading 14.3% below its estimated fair value. The current Market Cap is $1,077,331 Mil and 524480.5% above the Drug Manufacturers industry median of 205.37. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Eli Lilly and Co (LLY), the current Market Cap is $1,077,331 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of $1,208.12 is trading 14.3% below its estimated GF Value™ of $1,409.61.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for LLY:
Market Cap: $1,077,331 Mil
GF Value™: $1,409.61 vs. price of $1,208.12 (14.3% below fair value)
Industry Position: 524480.5% above the Drug Manufacturers median (#1 of 1023)
No single metric tells the full story. See the LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score
Get the complete analysis for LLY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LLY has been successfully added to your 
